MannKind Stock Jumps 5.7% as FDA Clears Furoscix ReadyFlow™ and Company Locks In $50M Placement

MannKind Corporation (MNKD) opened the morning with momentum, as its shares climbed 5.7% in premarket trading. Investors reacted quickly to two announcements that landed together: a fresh FDA approval and a newly secured $50 million financing deal.

Key Points

• MannKind (MNKD) rose about 5.7% in premarket trading following two simultaneous announcements.
• The FDA cleared Furoscix ReadyFlow™, a first-of-its-kind subcutaneous autoinjector that delivers IV-equivalent diuretic therapy for heart failure and chronic kidney disease patients without a hospital visit.
• The company secured a private placement expected to raise roughly $50 million in gross proceeds, led by Frazier Life Sciences and set to close on or about July 24, 2026.
• MannKind is issuing 10.44 million shares at $3.89 each, plus 2.41 million pre-funded warrants at $3.88 (with a $0.01 exercise price, immediately exercisable and no expiration).
• Net proceeds are earmarked for general corporate purposes, including a $45 million contingent value rights payment triggered by the Furoscix ReadyFlow™ approval.

FDA Greenlights a First-of-Its-Kind Device

First, the FDA cleared Furoscix ReadyFlow™, and the approval matters because it introduces something the market hasn’t seen before. Rather than requiring a hospital visit, the subcutaneous autoinjector delivers IV-equivalent diuretic therapy directly, giving patients with heart failure and chronic kidney disease a far more convenient option. As a result, MannKind now holds a differentiated product in a space where ease of administration carries real weight.

A $50M Private Placement Backs the Momentum

Alongside the approval, MannKind entered into a securities purchase agreement for a private placement that it expects will raise roughly $50 million in gross proceeds. Notably, biotech investment firm Frazier Life Sciences led the offering, which the company scheduled to close on or about July 24, 2026.

Breaking Down the Terms

To fund the raise, MannKind is issuing 10.44 million shares of common stock at $3.89 per share. In addition, select investors will receive 2.41 million pre-funded warrants in place of common stock, priced at $3.88 per warrant. These warrants come with an exercise price of just $0.01 per share, become exercisable immediately, and carry no expiration until investors exercise them in full.

Where the Money Goes

Finally, MannKind laid out how it intends to deploy the capital. The company plans to direct the net proceeds toward general corporate purposes, and specifically toward covering a $45 million contingent value rights payment — an obligation the recent Furoscix ReadyFlow™ approval triggered. In other words, the same milestone that boosted the stock also created a payment the raise now helps satisfy.